StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a research note released on Wednesday. The firm issued a hold rating on the stock. Separately, HC Wainwright dropped their target price on shares of Oncternal Therapeutics from $30.00 to $28.00 and set a buy rating on the stock in a report […]
Oncternal Therapeutics (NASDAQ:ONCT – Free Report) had its target price decreased by HC Wainwright from $30.00 to $28.00 in a report released on Monday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Oncternal Therapeutics’ Q1 2024 earnings at ($3.30) EPS, Q2 2024 earnings at […]
In this article, we will take a detailed look at the 10 Underperforming Stocks Insiders are Buying. For a quick overview of such stocks, read our article 5 Underperforming Stocks Insiders are Buying.
In this article, we will take a detailed look at the 10 Underperforming Stocks Insiders are Buying. For a quick overview of such stocks, read our article 5 Underperforming Stocks Insiders are Buying. Legendary investor Peter Lynch in his famous book “One Up On Wall Street” talked in detail about the importance of keeping tabs on insider buying […]